Impact of Anamorelin with unresectable pancreatic, gastric and colorectal cancer patients for a quality of life, skeletal muscle index and malnutrition

ABSTRACT: Primary outcome(s): Difference in QOL between non-Anamorelin usage and Anamorelin usage patients in 24 weeks (assessed by EORTC QLQ-C30)

DISEASE(S): Pancreatic Cancer Gastric Cancer Colorectal Cancer

PROVIDER: 2661537 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR